Insider · CIK 0001763026

Leen Ann M.

Reports to the SEC for 2 companies · JACKSONVILLE, FL

sec.gov

Transactions

Companies

Filings

CIK

0001763026

Forms 4 and 5

Insider transactions

36 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2023-02-02	KLRSKalaris Therapeutics, Inc.A Award	Chief Scientific Officer	AAward	+43.8K sh	—	—	124,006
2023-02-02	KLRSKalaris Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Chief Scientific Officer	AAward	+81.3K sh	—	—	473,594
2022-08-16	KLRSKalaris Therapeutics, Inc.A Award	Chief Scientific Officer	AAward	+15K sh	—	—	43,000
2022-07-01	KLRSKalaris Therapeutics, Inc.A Award	Chief Scientific Officer	AAward	+14K sh	—	—	65,256
2022-07-01	KLRSKalaris Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Chief Scientific Officer	AAward	+26K sh	—	—	392,344
2022-01-18	KLRSKalaris Therapeutics, Inc.A Award	Chief Scientific Officer	AAward	+23.3K sh	—	—	51,256
2022-01-18	KLRSKalaris Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Chief Scientific Officer	AAward	+56.7K sh	—	—	366,344
2021-11-16	KLRSKalaris Therapeutics, Inc.S Sale	Chief Scientific Officer	SSale	−100 sh	$21.76	−$2,176	2,288,154
2021-11-15	KLRSKalaris Therapeutics, Inc.S Sale	Chief Scientific Officer	SSale	−6,122 sh	$21.92	−$134K	2,288,254
2021-11-12	KLRSKalaris Therapeutics, Inc.S Sale	Chief Scientific Officer	SSale	−14.3K sh	$22.26	−$318K	2,294,876
2021-11-12	KLRSKalaris Therapeutics, Inc.S Sale	Chief Scientific Officer	SSale	−500 sh	$23.18	−$11.6K	2,294,376
2021-05-10	KLRSKalaris Therapeutics, Inc.S Sale	Chief Scientific Officer	SSale	−150K sh	$22.75	−$3.41M	2,309,142
2021-03-16	KLRSKalaris Therapeutics, Inc.S Sale	Chief Scientific Officer	SSale	−3,025 sh	$30.00	−$90.8K	2,459,142
2021-03-01	KLRSKalaris Therapeutics, Inc.S Sale	Chief Scientific Officer	SSale	−6,359 sh	$38.46	−$245K	2,465,326
2021-03-01	KLRSKalaris Therapeutics, Inc.S Sale	Chief Scientific Officer	SSale	−3,159 sh	$39.18	−$124K	2,462,167
2021-02-23	KLRSKalaris Therapeutics, Inc.S Sale	Chief Scientific Officer	SSale	−1,492 sh	$38.83	−$57.9K	2,474,392
2021-02-23	KLRSKalaris Therapeutics, Inc.S Sale	Chief Scientific Officer	SSale	−1,907 sh	$39.59	−$75.5K	2,472,485
2021-02-23	KLRSKalaris Therapeutics, Inc.S Sale	Chief Scientific Officer	SSale	−800 sh	$40.56	−$32.4K	2,471,685
2021-02-22	KLRSKalaris Therapeutics, Inc.S Sale	Chief Scientific Officer	SSale	−1,200 sh	$41.54	−$49.8K	2,480,390
2021-02-22	KLRSKalaris Therapeutics, Inc.S Sale	Chief Scientific Officer	SSale	−4,506 sh	$42.84	−$193K	2,475,884
2021-02-19	KLRSKalaris Therapeutics, Inc.S Sale	Chief Scientific Officer	SSale	−7,541 sh	$41.75	−$315K	2,481,590
2021-02-18	KLRSKalaris Therapeutics, Inc.S Sale	Chief Scientific Officer	SSale	−300 sh	$39.20	−$11.8K	2,491,531
2021-02-18	KLRSKalaris Therapeutics, Inc.S Sale	Chief Scientific Officer	SSale	−1,100 sh	$40.44	−$44.5K	2,490,431
2021-02-18	KLRSKalaris Therapeutics, Inc.S Sale	Chief Scientific Officer	SSale	−1,300 sh	$41.50	−$54K	2,489,131
2021-02-17	KLRSKalaris Therapeutics, Inc.S Sale	Chief Scientific Officer	SSale	−500 sh	$38.63	−$19.3K	2,493,617
2021-02-17	KLRSKalaris Therapeutics, Inc.S Sale	Chief Scientific Officer	SSale	−400 sh	$39.85	−$15.9K	2,493,217
2021-02-17	KLRSKalaris Therapeutics, Inc.S Sale	Chief Scientific Officer	SSale	−1,386 sh	$41.28	−$57.2K	2,491,831
2021-02-16	KLRSKalaris Therapeutics, Inc.S Sale	Chief Scientific Officer	SSale	−2,850 sh	$41.82	−$119K	2,494,317
2021-02-16	KLRSKalaris Therapeutics, Inc.S Sale	Chief Scientific Officer	SSale	−200 sh	$42.79	−$8,558	2,494,117
2021-01-19	KLRSKalaris Therapeutics, Inc.A Award	Chief Scientific Officer	AAward	+28K sh	—	—	28,000
2021-01-19	KLRSKalaris Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Chief Scientific Officer	AAward	+52K sh	—	—	52,000
2020-11-30	KLRSKalaris Therapeutics, Inc.G Gift	Chief Scientific Officer	GGift	−60.4K sh	—	—	0
2020-11-30	KLRSKalaris Therapeutics, Inc.G Gift	Chief Scientific Officer	GGift	+60.4K sh	—	—	60,394
2020-08-03	KLRSKalaris Therapeutics, Inc.C Conversion	Chief Scientific Officer	CConversion	+2.44M sh	—	—	2,436,773
2020-08-03	KLRSKalaris Therapeutics, Inc. · Series A-3 Convertible Preferred StockC Conversion	Chief Scientific Officer	CConversion	−3.63M sh	—	—	0
2020-07-29	KLRSKalaris Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Chief Scientific Officer	AAward	+258K sh	—	—	257,600

Recent filings

Accepted (ET)
Feb 34
Leen Ann M.0001209191-23-006990
SEC(opens sec.gov)
Aug 174
Leen Ann M.0000899243-22-029062
SEC(opens sec.gov)
Nov 164
Leen Ann M.0000899243-21-044889
SEC(opens sec.gov)
May 104
Leen Ann M.0001209191-21-031337
SEC(opens sec.gov)
Mar 184
Leen Ann M.0001209191-21-021808
SEC(opens sec.gov)
Mar 34
Leen Ann M.0001209191-21-017527
SEC(opens sec.gov)
Feb 234
Leen Ann M.0001209191-21-013484
SEC(opens sec.gov)

Companies

Address

5 WEST FORSYTH STREET SUITE 200

JACKSONVILLE, FL, 32202